Literature DB >> 20215818

Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens: the role of prostate volume and the number of positive cores.

Carles X Raventós1, Anna Orsola, Inés de Torres, Lluís Cecchini, Enrique Trilla, Jacques Planas, Joan Morote.   

Abstract

INTRODUCTION: To determine clinical and biopsy features with predictive capacity to identify pathologically insignificant prostate cancer (pIPCa).
MATERIAL AND METHODS: pIPCa was defined as cancer volume <0.5 cm(3) and a Gleason score (GS) of <or=6 in radical prostatectomy (RP) specimens. Clinical and biopsy parameters were studied as predictors of pIPCa and validated by applying them to d'Amico's low-risk cases: T1c-T2a, prostate-specific antigen (PSA) <10 and biopsy GS <or=6. Appropriate cut-offs were selected.
RESULTS: 280 patients were evaluated; 11.8% (33) had pIPCa, increasing to 23% in low-risk cases. In patients fulfilling d'Amico's low-risk criteria, variables significantly different in pIPCa were: volume, number of positive cylinders (NPC), percentage of positive cylinders (%PC), percentage of the most affected cylinder (%MAC) and uni/bilaterality. In these cases, volume and the NPC increased as independent variables on logistic regression and when adding a volume threshold of 45 cm(3) and 1 positive core, specificity reached 95.8%.
CONCLUSIONS: The incidence of pIPCa in RP specimens is relevant, especially in low-risk cases. Prostate volume and NPC are independent predictors of pIPCa. We propose a simple predictive model by adding the features of 1 positive core and volume >or=45 cm(3) to d'Amico's criteria. This allows to preoperatively distinguish between patients that most probably would benefit from radical treatment and patients that might be offered active surveillance. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20215818     DOI: 10.1159/000277591

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Automated computer-derived prostate volumes from MR imaging data: comparison with radiologist-derived MR imaging and pathologic specimen volumes.

Authors:  Julie C Bulman; Robert Toth; Amish D Patel; B Nicolas Bloch; Colm J McMahon; Long Ngo; Anant Madabhushi; Neil M Rofsky
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

2.  Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.

Authors:  Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Giovanni Novella; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Aliasger Shakir; Arianna Mariotto; Matteo Brunelli; Maria Angela Cerruto; Giovanni Enrico Cacciamani; Filippo Migliorini; Salvatore Siracusano; Walter Artibani
Journal:  World J Urol       Date:  2019-06-01       Impact factor: 4.226

Review 3.  Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

4.  Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies.

Authors:  Bumsoo Park; Seong-Soo Jeon; Sung-Ho Ju; Byong-Chang Jeong; Seong-Il Seo; Hyun-Moo Lee; Han-Yong Choi
Journal:  Asian J Androl       Date:  2012-12-31       Impact factor: 3.285

5.  Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer.

Authors:  Yu Zhang; Na Zeng; Yi Chen Zhu; Yang Xin Rui Huang; Qiang Guo; Ye Tian
Journal:  World J Surg Oncol       Date:  2018-06-01       Impact factor: 2.754

6.  Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10 ng/ml: results of 564 consecutive cases.

Authors:  Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Aliasger Shakir; Giovanni Novella; Marco Pirozzi; Tania Processali; Riccardo Rizzetto; Nelia Amigoni; Leone Tiso; Clara Cerrato; Matteo Brunelli; Maria Angela Cerruto; Filippo Migliorini; Salvatore Siracusano; Walter Artibani
Journal:  Ther Adv Urol       Date:  2019-08-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.